Nicox Sa · EURONEXT:ALCOX
Nicox Sa — Investor Presentation (April 2025)
31 slides from Nicox Sa's investor presentation, Apr 30, 2025
Slide 1: Nicox Corporate Presentation
Nicox Corporate Presentation An international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health April 30, 2025 Euronext Growth Paris: ALCOX September 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to, an
Slide 3: 2025 Opportunities Building on 2024 Achievements
2025 Opportunities Building on 2024 Achievements 1 ✔ Appointment of Gavin Spencer as Chief Executive Officer ✔ Nicox Board entirely renewed with appointment of Damian Marron as Chair and 3 new Board members ✔ Restructuring of debt agreements with BlackRock NICOX visible science ✔ Streamlining costs
Slide 4: Consistently Delivering Innovations in Ophthalmology
Consistently Delivering Innovations in Ophthalmology … … with NCX 470 the Next Derisked Asset Advancing Toward NDA Filing in the U.S. and China Commercial Value of Lead Asset NCX 470 in Global Partnerships with Deep Ophthalmology NICOX visible science Late-Stage Phase 3 Tier 1 Ophthalmology Players
Slide 5: Upcoming Milestones
Upcoming Milestones NCX 470 ZERVIATE Corporate NICOX visible science ❖ Whistler results – Q2 2025 ❖ Ongoing partnership discussions ❖ Recurrent revenue ❖ Denali results – Q3 2025 ❖ Potential NCX 1728 license ❖ Estimated potential worldwide option exercise with Glaukos sales over $300 million1 1. Wit
Slide 6: An Innovative Portfolio Led by NCX 470
An Innovative Portfolio Led by NCX 470, a Derisked Product Candidate with Global Potential Stages of Development 3 Product Candidates Preclinical Phase 1 Phase 2 Phase 3 NDA Marketed Status Denali topline results expected in NCX 470 | NO-Donating Bimatoprost Eye Drops Q3 2025 Glaucoma & Ocular Hyper
Slide 7: Glaucoma: a Worldwide Ophthalmic Condition with Unmet Medical Needs
Glaucoma: a Worldwide Ophthalmic Condition with Unmet Medical Needs Elevated IOP* Contributes to Irreversible Optic Nerve Damage, Leading to Progressive Vision Loss NICOX visible science As published in the landmark EMGT study “…each mmHg of decreased IOP was related to an approximately 10% lowering
Slide 8: Unmet Medical Needs for Glaucoma Treatment
Unmet Medical Needs for Glaucoma Treatment ✔ 40% of patients do ✔ Many patients ✔ Tolerability issues Despite having well established not achieve their require >1 with some NICOX visible science first-line therapies, including the target IOP on medication which medications lead standard-of-care, lat
Slide 9: Value Proposition of NCX 470
Value Proposition of ✔ Novel molecule with positive impact on lowering IOP, the leading cause of glaucoma NCX 470 ✔ Positive pivotal Phase 3 topline results from the Mont Blanc trial1,2,3 ✔ First non-combination product to demonstrate statistical non-inferiority to a prostaglandin analog in a pivota
Slide 10: NCX 470 Timing
NCX 470 Timing A Near-Term Asset Close to Completion of Development Q3 2025 H1 2026 H1 2027 NICOX visible science Topline Results of Submission of New Approval and Denali Phase 3 Drug Application in Potential Launch in Clinical Trial the United States* the United States* • Composition of matter pate
Slide 11: NCX 470 Lowers IOP Through a Validated Dual Mechanism Pathway
NCX 470 Lowers IOP Through a Validated1 Dual Mechanism Pathway Clinically Validated with the First NO-Donating PGA, VYZULTA® Two Pathways for Aqueous Humor Outflow 1 Primary or conventional outflow normally accounts Stimulated by NICOX visible science for ~60% to 80% of nitric oxide (NO) outflow 2 S
Slide 12: Positive NCX 470 Mont Blanc Topline Results
Positive NCX 470 Mont Blanc Topline Results1,2,3 Phase 3 Clinical Program Intended to Support U.S. & China NDA Submissions Designed to demonstrate safety and efficacy of NCX 470 0.1% vs. latanoprost 0.005%, studies will evaluate reduction of IOP from time-matched baseline at pre-established time poi
Slide 13: Mont Blanc Phase 3 Efficacy Trial Design
Mont Blanc Phase 3 Efficacy Trial Design1 Designed to Evaluate NCX 470 vs. Established Therapy, Latanoprost Randomized, controlled, double-masked, parallel design trial. Patients with open angle glaucoma or ocular hypertension were randomized 1:1 to once-daily treatment with NCX 470 0.1% or latanopr
Slide 14: Significant, Sustained IOP-Lowering Effects
Significant, Sustained IOP-Lowering Effects IOP-Lowering from Baseline Was 8.0 to 9.7 mmHg for NCX 470 vs. 7.1 to 9.4 mmHg for Latanoprost NCX 470 0.1%: N = 328 Latanoprost 0.005%: N = 333 NICOX visible science • Denotes statistically significant differences vs latanoprost (p<0.049) 14 • Fechtner et
Slide 15: Mont Blanc Topline Results Demonstrate Robust Efficacy and Safety
Mont Blanc Topline Results Demonstrate Robust Efficacy and Safety 1,2 All Comparisons Are Based on NCX 470 0.1% and Latanoprost 0.005% Topline Results from this Pivotal Trial: • IOP-lowering effect from baseline was 8.0 to 9.7 mmHg for NCX 470 vs. 7.1 to 9.4 mmHg for latanoprost • Statistical non-in
Slide 16: NCX 470 Post hoc Analysis Further Differentiates vs Standard of Care
NCX 470 Post hoc Analysis Further Differentiates vs Standard of Care All Comparisons Are Based on NCX 470 0.1% and Latanoprost 0.005% • Statistically significantly greater percentage of patients achieve ≤ 18mmHg IOP on NCX 470 compared to latanoprost • Mean percentage reduction in IOP greater on NCX
Slide 17: Mont Blanc Results Published in a Prestigious Journal
Mont Blanc Results Published in a Prestigious Journal NICOX visible science Authors’ Conclusion: The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhance
Slide 18: NCX 470 Presentations at Key Ophthalmology Conferences
NCX 470 – Presentations at Key Ophthalmology Conferences • Poster: Diurnal IOP Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC Trial 2025 NICOX visible science • Poster 1: Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Basel
Slide 19: Nitric Oxide May Protect the Retina
Nitric Oxide May Protect the Retina N I C O X V IS IB L E S C I E N C E NO elicits NO inhibits NO & PGA vasorelaxation & inflammatory lower IOP improves ocular cytokines & blood flow oxidative stress Potential retinal benefits 19
Slide 20: NCX 470 Shows Retinal Cell Protection in a Nonclinical Model
NCX 470 Shows Retinal Cell Protection in a Nonclinical Model 1,2 Improved ocular perfusion and retinal function in damaged eyes vs. Lumigan® Ocular hemodynamics Retinal function (Echo-doppler - Ophthalmic artery) (Scotopic Electroretinogram - rod/cone responses) N I C O X V IS IB L E S C I E N C E O
Slide 21: Ongoing Whistler Trial: results expected Q2 2025
Ongoing Whistler Trial: results expected Q2 2025 Designed to Evaluate NCX 470 Mechanism of Action Double-masked, placebo-controlled trial. Healthy volunteers or patients with ocular hypertension are randomized to receive NCX 470 0.1% in one eye and placebo in the fellow eye once daily for 8 days. N
Slide 22: U.S. Glaucoma Clinical Advisory Board with Leading Experts
U.S. Glaucoma Clinical Advisory Board with Leading Experts DR. ROBERT D. FECHTNER, MD, CHAIRMAN DR. STEVEN MANSBERGER, MD MPH Professor and Chair of the Department of Ophthalmology at Vice-Chair, Senior Scientist, and Director of Glaucoma Services and SUNY Upstate Medical University, Syracuse, NY Op
Slide 23: Chinese Partner Ocumension Therapeutics
Chinese Partner and Nicox Shareholder, Dedicated to Ophthalmology with Manufacturing and Commercial Capabilities Portfolio of 25 NICOX visible science Listed on the 444 Employees, Based in China Products with Hong Kong Stock 10 Commercialised Including 232 in Created in 2018 Exchange Since $34 Milli
Slide 24: Kowa: Global Enterprise with Japanese Glaucoma Franchise
Global Enterprise with a Strong Pharmaceutical Business and Japanese Glaucoma Franchise Founded in Japan NICOX visible science in 1894 ~8000 Employees The Pharmaceutical Team of Medical Active Worldwide with an Annual Sector is an Representatives in Multiple Group Revenue of Important One with in Ja
Slide 25: Future Commercialization of NCX 470
Future Commercialization of NCX 470 To Secure the Long-Term Future of the Company ▪ The Company is considering a number of options to ensure the commercialization of NCX 470 and concretize the future strategy: NICOX visible science • New license agreements • Joint venture structures with companies h
Slide 26: Existing Commercial Products and Partnerships
Existing Commercial Products and Partnerships VYZULTA ✔ Same mechanism of action as NCX 470 ✔ Launched by Bausch + Lomb in 2017 in the United States ✔ Marketed in >15 countries and territories NICOX visible science ✔ Revenue sold to Soleus Capital in October 2024 ZERVIATE1 ✔ 5% to 9% royalties on an
Slide 27: NCX 1728: Research Collaboration with Glaukos
NCX 1728: Research Collaboration with Glaukos NO-donating PDE5 inhibitor MOA for this novel class of molecules is based entirely Combining NO- on NO-mediated activity Release with PDE5 Inhibition NO-mediated effects are enhanced and prolonged by concomitant phosphodiesterase-5 (PDE5) inhibition with
Slide 28: Experienced Leadership Team
Experienced Leadership Team Gavin Spencer Sandrine Gestin Doug Hubatsch NICOX visible science Emmet Purtill Chief Executive Officer VP, Finance and HR EVP, Chief Scientific Officer VP Business Development Sonia Benhamida Observer BlackRock Damian Marron Christine Placet Marc Le Bozec Gavin Spencer C
Slide 29: Financial Highlights
Financial Highlights Cash Balance Expected to Support Current Operations into Q4 2025 Financial Position and Ownership of Nicox SA 1 Cash, Cash Equivalents as at 31 December 2024 €10.5 million NICOX visible science Long Term Debt as at 31 December 2024 €15.1 million Cash Runway2 Q4 2025 Outstanding
Slide 30: Investment Highlights
Investment Highlights ✓ A Proven Track Record in Clinical Development and Business Development • Two product approvals in the U.S., one in China • Business Development deals in the U.S., Japan, China, and globally with Tier 1 companies NICOX visible science ✓ NCX 470, a Derisked, Late-Stage Developm
Slide 31: Nicox S.A. contact details
Nicox S.A. Sundesk Sophia Antipolis Emerald Square Bâtiment C communications@nicox.com rue Evariste Galois, 06410 Biot, France www.nicox.com T: +33 (0)4 97 24 53 00 31